Nicola Monteleone

Readiness for the journey….

39

Today is the International Day for the Elimination of Violence against Women, an essential occasion to shed light on the burden of gender violence. As part of Angelini Industries and on a journey to raise awareness around brain and mental health with Angelini Pharma, I've decided to focus on a critical yet invisible impact of gender violence: its toll on mental health. Violence against women, in fact, deeply impacts mental health, doubling the risk of depression and increasing PTSD and suicide risk among survivors.  You can read the full article here: https://lnkd.in/diYgWtMT #NoExcuse #AngeliniPharma #EveryStepCloser #WithYouInMind

198

1 commento

Gruppo Servier in Italia teams have launched a major information and awareness campaign on the importance of therapeutic adherence in treating chronic cardiovascular diseases. In partnership with SIPREC - Italian Society for Cardiovascular Prevention, the Affetti Desiderati campaign provides patients with access to a range of educational materials that highlight the importance of therapeutic adherence for treating cardiovascular diseases. The objective is to build awareness among the general public and health care professionals on how important it is for patients to correctly follow their prescribed treatment to improve their quality of life. This innovative campaign aims to further reinforce patient understanding and engagement in relation to their treatment, helping improve their health and their quality of life. The campaign uses an original metaphor, presenting therapeutic adherence to treatment as a love story. Servier Italy and the Italian Society for Cardiovascular Prevention (SIPREC) are demonstrating their determination to combat non-adherence and promote better cardiovascular health for all. Treatment adherence is a major public health issue. According to the WHO, less than 50% of patients around the world follow their prescribed treatment correctly. This issue has a particular impact on patients with chronic diseases, including cardiovascular diseases, which involve lifelong treatments. Viviana Ruggieri, Head of External Relations, Servier Group in Italy: “Therapeutic adherence is crucial for the Servier Group in Italy, through both its value and its impact in terms of corporate social responsibility. Leading the way in cardiometabolism, we have worked for years to build awareness among patients, health care professionals and Institutions on this issue.” #awarenesscampaign #therapeuticadherence #aderenzaterapeutica #cardiovasculardiseases #SIPREC #Servier #PatientFirst #MovedByYou 👉 https://lnkd.in/dufjEaGJ

29

1 commento

In this very important day #COPDDay I think we must play more attention to SMOKING CESSATION: please read this Surgeon General’s Report on tobacco-related health disparities in the United States. This report recognizes that while we’ve made remarkable progress reducing tobacco use in the past 60 years, that progress has not been even. Smoking remains the leading preventable cause of disease and death in the United States. Cigarette smoking and exposure to secondhand tobacco smoke cause nearly half a million deaths in the United States each year—nearly one in five of all deaths. https://lnkd.in/deq6Q7JE from Dr. Vivek Murthy Surgeon General's Report Società Italiana di Pneumologia Corsi e Congressi AIPO Ricerche Centers for Disease Control and Prevention

5

🌍✨ Today marks World Asthma Day 2024! ✨🌍 On this day, let's celebrate the remarkable resilience of individuals living with asthma. They defy the constraints of their condition, surpassing limits, and embracing life to the fullest. At Chiesi we are honored to share compelling stories of patients who have defied the limitations imposed by their condition. Today, we shine a spotlight on their inspirational journeys, highlighting their resilience and determination in overcoming the challenges of living with asthma. Behind these inspiring individuals lie stark statistics: Asthma is one of the most common chronic non-communicable diseases that affects over 260 million worldwide, leading to 450,000 annual deaths, many of which could have been prevented. Join us in honoring our patients and raising awareness about this respiratory disease. Happy World Asthma Day! 🌍 #Limitless #Sustainability #RespiratoryHealth

34

🤳 𝐂𝐃𝐌𝐎 𝐌𝐚𝐫𝐤𝐞𝐭 𝐔𝐩𝐝𝐚𝐭𝐞𝐬 𝐓𝐡𝐢𝐬 𝐖𝐞𝐞𝐤 🔄 Alfasigma has rebranded its CDMO Business Unit as Morpho, underscoring its growth and leadership in the pharmaceutical industry. Established in 2017, Alfasigma’s CDMO arm has built a strong reputation in third-party pharmaceutical development and manufacturing. The rebrand as Morpho reflects the company's evolution and future ambitions to expand its capabilities in the sector. 🤝 Matica Biotechnology, Inc. and CytoImmune Therapeutics have entered a strategic partnership to advance cell therapy targeting cancer. Matica will produce viral vectors at its Texas GMP facility, while CytoImmune will manufacture the cell therapies in Puerto Rico. The collaboration aims to accelerate clinical trials and the development of new cancer therapies. ⚙️ Evonik is refocusing its Health Care division on high-growth sectors like complex APIs, drug delivery systems, and biosolutions such as lipids for mRNA and gene therapies. As part of this shift, the company will discontinue keto acid production at its Hanau facility by the end of 2025, affecting 260 employees, who will receive support for job transitions. 💉 Kindeva Drug Delivery has completed its first registration batch at its high-volume injectable manufacturing site in Bridgeton, marking a major milestone. The facility, designed to expand injectable production, will install three additional production lines over the next 18 months to meet increasing demand for pharmaceutical products. 📊 Cellipont Bioservices has named Darren Head as CEO, further strengthening its leadership as the company embarks on an expansion phase. The appointment coincides with a minority growth equity investment from HealthQuest Capital, which, alongside continued backing from GPP, will fuel Cellipont’s growth in cell and gene therapy manufacturing. 🌍 MilliporeSigma has opened a €290 million biosafety testing and cell banking facility in Rockville, Maryland. This state-of-the-art 23,000-square-meter complex consolidates operations into one building, enhancing efficiency, collaboration, and automation to meet rising global demand for biosafety and analytical testing services. 🏭 Ardena has acquired Catalent Pharma Solutions's state-of-the-art facility in Somerset, NJ, enhancing its late-stage and small-scale commercial manufacturing capabilities for oral drug products. This acquisition supports Ardena’s goal to offer end-to-end pharmaceutical development solutions across its global network of GMP facilities. 🚀 Thermo Fisher Scientific has launched Accelerator Drug Development, expanding its CDMO and CRO services. This follows significant upgrades to its Middleton, WI, GMP facility and expansions in Cincinnati, OH, and Bend, OR, which will boost manufacturing and testing capabilities for oral solid dose drugs, addressing issues like solubility and bioavailability in pharma and biotech development. Stay tuned for more industry highlights! #CDMO #News

9

Menarini Group signs licensing deal with Insilico for promising cancer treatment The asset is a highly selective and potentially best-in-class small molecule inhibitor targeting a broad range of solid tumor cancers, developed with the help of Chemistry42, Insilico's generative chemistry engine, and Insilico's drug discovery team. The asset has successfully completed preclinical development and has demonstrated broad anti-tumor activity in selected cancers. Source:

1

#Uprising We are thrilled to announce that Zambon recently become a part of #PharmaSynergyOTC 2024! PharmaSynergyOTC, a global event taking place on September 12-13 at Les Salons Hoche in Paris, presents a unique opportunity for companies specializing in OTC and consumer health products to connect, learn, and engage in discussions about commercial partnerships. We believe that in the dynamic landscape of pharmaceuticals and consumer healthcare, networking is about meaningful connections. At PharmaSynergy OTC events, our focus is clear: Over-the-counter, Consumer Healthcare, Nutraceuticals, Dermocosmetics, and Medical Devices (OTC). This targeted approach ensures that every interaction is purposeful, leading to fruitful connections, discussions and collaborations. For registration details, please visit our website at https://lnkd.in/gFtazD6 or get in touch via [email protected] #NOT_JUST_ANOTHER_EVENT #PRODUCT_FOCUSED_PARTNERING_EVENT #Over_the_Counter #OTC #ConsumerHealthcare #CHC #Dermocosmetics #OTCmedicaldevices #FSMP #BusinessDevelopment #B2Bpartnering #Distribution #Efficient_B2B_Partnering #therapeutic_indication #geographical_presence #collaboration_type #Growth_stimulating_Insights #trends #growthOpportunities #analytics #growth_pockets

7

🌍 World Pharma Today recently had the opportunity to interview Evotec, a pioneering biotechnology company, during the CPHI Milan event at #FieraMilano, #Italy. I'm thrilled to share insights from this conversation, highlighting Evotec's innovative contributions that are driving the future of biotech. Stay connected for more updates from this exciting event! #CPHIMilan #Evotec #Biotechnology #PharmaInnovation #FieraMilano #WorldPharmaToday

11

Check out AUX-001 Phase 1a results presented at European Society of Cardiology annual meeting in London by Uwe Tigör, MD, our Chief Medical Officer at Auxilius Pharma. Phase 1a study explored the safety, tolerability, and pharmacokinetics of our compound, which is promising new medication for chronic stable angina. Now that the meeting’s embargo has lifted, we’re thrilled to share these results with you! Check out the attached presentation for more details. If you’d like the full version of the deck, feel free to reach out directly to @Uwe Tigör, MD or to me #cardiology #CSAP #AUX001 #ESC #newmedication #biotech #news

48

🎉So proud of my Italian colleagues who pave the way! 🏆Teva Italy obtained the Gender Equality Certification, recognized and supported by the State as part of the National Recovery and Resilience Plan. 🌟As part of the ESG strategy, we are fully committed in implementing a D&I culture across the organization; in line with this several initiatives have been put in place in the Italian affiliate in the recent past, in order to have an organization based on #equality #inclusion #diversity principles. 🔥As a result, 53% of employees are women and managerial roles are covered 65% by women, far above country average. 🙌This certification marks a key milestone in this journey which we are still on, with a mindset of continuous improvement. 🇮🇹In Italy only few companies obtained the Gender Equality Certification, and we are amongst the first pharma companies. It is a privilege to be driving such a cultural change in the industry and in the society! Giordana Cortinovis Umberto Comberiati Serena Corazzina #tevaitalia #teva #genderequality #InclusionAndDiversity #tevalife

26

#ClimateChange is impacting global health, particularly those more vulnerable to the threats of #airpollution, such as people with respiratory conditions. At Chiesi, we strongly believe that #patients should not have to shoulder the burden of environmental responsibility when considering treatment options that affect their #health. Learn more by watching the episode “How Redesigning Inhalers Could Reduce Their Environmental Impact” sponsored by Chiesi and produced by BBC StoryWorks: https://lnkd.in/dCTQNiez #EarthDay #ActionOverWords #TheClimateAndUs

233

Faster access in Italy and prioritisation of innovative drugs that address unmet need—these are the ambitions of AIFA Agenzia Italiana del farmaco following its recent reorganisation. Roberto Nisticò, the Agency’s new President, made these commitments in his first meeting with Marcello Cattani, the President of Farmindustria (tinyurl.com/y5xrudu4).   In a press release, Nisticò said: “We are working to reduce the time of access procedures with a reduction of bureaucracy and with administrative simplification, ensuring that citizens may quickly use truly innovative medicines.” To that end, a technical working group has been established to identify simplification tools that will prioritise the approval of drugs that can improve the quality of care and expand the therapeutic options available. In addition, the Scientific and Economic Committee (CSE) will be relieved of certain (unspecified) procedures that could be carried out automatically. The CSE will hold more frequent meetings in the short term to clear the backlog of applications that has built up “because our goal is to prioritise drugs that fill a therapeutic gap,” according to Nisticò.   A new online platform for access authorisation procedures will be established. Pierluigi Russo, AIFA’s Technical and Scientific Director, says the objective is “to make communication between companies and the Agency more effective and transparent concerning the CSE process, in addition to updating the guideline on the dossiers for requesting the price and reimbursement of medicines.”   Addressing problems associated with antimicrobial resistance will also be high on AIFA’s agenda. There is a need for incentives and rapid approval pathways for novel antibiotics. Nisticò believes “an effective model is the legislation that has allowed to incentivise the research for orphan drugs for rare diseases, which can be duplicated for new antibiotics not resistant to bacterial infections. But this will require legislative action, also at a European level, and we will commit to raising awareness among decision-makers at various levels.”   AIFA has confirmed that it will apply the EU Regulation on Health Technology Assessment and make use of joint clinical assessment reports. They will help to support “a multidimensional evaluation of the drug on the healthcare system, economic aspects and protection of citizens' health.” #Italy #AIFA #HTA #marketaccess #innovation

88

🌟 Exciting News! 🌟 #CPHIMilan #PharmaEvent #WorldPharmaToday #CPHIMilan #WorldPharmaToday #PharmaEvents #PharmaceuticalInnovation

2

Yesterday, I had the opportunity to represent Sanofi at 𝗠𝗼𝗺𝗸𝗲𝘁𝗶𝗻𝗴 𝟮𝟬𝟮𝟰. 𝗠𝗼𝗺𝗸𝗲𝘁𝗶𝗻𝗴 is the Italian conference, organized by FattoreMamma, 𝗱𝗲𝗱𝗶𝗰𝗮𝘁𝗲𝗱 𝘁𝗼 𝗺𝗮𝗿𝗸𝗲𝘁𝗶𝗻𝗴 𝘄𝗶𝘁𝗵 𝗮 𝗳𝗼𝗰𝘂𝘀 𝗼𝗻 𝗺𝗼𝗺𝘀 𝗮𝗻𝗱 𝗳𝗮𝗺𝗶𝗹𝗶𝗲𝘀. The opportunity to meet and share trends and best practices. I had the chance to present our journey of the last 3 years with our #𝗧𝗼𝗴𝗲𝘁𝗵𝗲𝗿𝗔𝗴𝗮𝗶𝗻𝘀𝘁𝗥𝗦𝗩 𝗰𝗮𝗺𝗽𝗮𝗶𝗴𝗻 𝘁𝗼 𝗿𝗮𝗶𝘀𝗲 𝗽𝗮𝗿𝗲𝗻𝘁𝘀 𝗮𝗻𝗱 𝗳𝗮𝗺𝗶𝗹𝘆 𝗮𝘄𝗮𝗿𝗲𝗻𝗲𝘀𝘀 𝗼𝗻 𝗥𝗲𝘀𝗽𝗶𝗿𝗮𝘁𝗼𝗿𝘆𝗦𝘆𝗻𝗰𝘆𝘁𝗶𝗮𝗹𝗩𝗶𝗿𝘂𝘀 (#RSV). Based on our experience, I think there are some key elements that companies approaching this type of initiative need to consider and adapt to their context/industry. 👂 𝗟𝗶𝘀𝘁𝗲𝗻𝗶𝗻𝗴: companies must have the ability to actively listen their target audience, understand their needs and their evolution over time. 🔄 𝗖𝗼-𝗖𝗿𝗲𝗮𝘁𝗶𝗼𝗻: Companies should directly engage their communities in co-creation projects and activities. This helps build trust and can lead the community to support and disseminate the initiatives carried out by the company, in a kind of widespread activism. 📳 👨‍👩‍👧‍👦 𝗖𝗿𝗲𝗮𝘁𝗲 𝗘𝘅𝗽𝗲𝗿𝗶𝗲𝗻𝗰𝗲𝘀...𝘆𝗲𝘀 𝗯𝘂𝘁 𝗵𝘆𝗯𝗿𝗶𝗱: The company's ability to intercept what is relevant to its target audience is essential. The importance of awareness campaigns is to connect with communities not only in a mediated relationship on screens but also directly, in person. ✅ 𝗧𝗿𝘂𝘀𝘁𝗮𝗯𝗶𝗹𝗶𝘁𝘆: The importance of having reliable and scientifically correct information, that is at the same time communicatively effective. 📢 𝗘𝗳𝗳𝗲𝗰𝘁𝗶𝘃𝗲 𝗖𝗼𝗺𝗺𝘂𝗻𝗶𝗰𝗮𝘁𝗶𝗼𝗻: importance for companies to be able to tailor communication, authentically, to the right tool, with the right tone by leveraging the strengths that each tool provides. ⬇️ In the video below what we built on our journey.. #TogetherAgainstRSV #prevention #sanofistories

60

2 commenti

Many people in my network, incl. those from the industry, keep asking me “what exactly is your new company doing”? If anything – it’s a call to action for us Alfasigma to build stronger employer branding, especially outside of Italy. One step at a time, here is my “Alfasigma 101”! ▶ We are privately-owned Italian multinational pharma group with a focus on innovative medicines and consumer healthcare. Starting in 1948 in Bologna, Alfasigma grew to become Top 5 pharma player in Italy with our products being sold in more than 100 markets. Our key focus is Gastro, Vascular and Rheumatology with a portfolio of Innovative Rx and consumer healthcare products. Being private allows to focus on doing what’s right while avoiding the pressure of “pleasing” financial markets. The last 2 years were truly transformational as Alfasigma embarked on a journey to build even stronger portfolio and become a truly global player. ▶ We strengthened consumer portfolio with Sofar S.p.A. acquisition in Italy, also actively leveraging it across C&EE and Emerging Markets. A strong presence in US was established with acquisition of Intercept Pharmaceuticals. Acquisition of JAK-i business from Galapagos gave us an opportunity to enter Rheumatology and expand presence in Western Europe. The two bio-tech acqusitions also gave us an R&D pipeline which will fuel further growth. We are also actively looking to expand our geo footprint further – from Latin America to Asia. ▶We doubling business in 3 years, looking to repeat it again, not only through "what" we do, but also "how". Being an ambitious mid-size player, we can’t win through “mass” – rather by being faster, more agile, more entrepreneurial. Its best told by two of our values – “Learn to Dare” and “Think Big, Act Small”, which really tell about a new DNA of Alfasigma. None of that is a rocket science – yet this is where Big Pharma often fails and where we are thriving. ▶ We are not (yet) as big as J&J or don’t have (yet) that much spotlight as NovoNordisk – but we are at a time and place when company reinvents itself and builds a new future. A great place to be if you are excited by growth and ambitions and don’t mind to roll your sleeves! We are growing and every day there is a new opportunity – especially at Alfasigma Growth Markets which spreads from LATAM to C&EE, MEA and Asia. If you feel that your hands are tied with endless ppt slides and your ideas take forever to happen – check out Alfasigma, even if you have not heard about us before. There could be more than meets the eye! We are looking for new colleagues but also open for different partnership opportunities. “Bookmark” Alfasigma in your mind – there is a lot come!

370

22 commenti

Ottimo spunto anche per le Società Scientifiche Italiane: British Journal of Pain 2024, Vol. 0(0) 1–26 https://lnkd.in/dd2QzutA "The British Pain Society updated their recommendations on intrathecal drug delivery (ITDD) for the management of pain and spasticity in adults. The recommendations are primarily evidence based but where necessary comprise the consensus opinion of the working group. The recommendations are accompanied by information for patients and their carers, intended to inform and support patients in their decision making. The updated guidance includes recent evidence base of ITDD use in pain and spasticity, address the issues of drug pump compatibility following the latest manufacturer and Medicines and Healthcare products Regulatory Agency (MHRA) recommendations as well as provide an update on the indications and complication management particularly endocrine complications and intrathecal granuloma formation." AISD Staff dell'Associazione Italiana Studio Dolore SIAARTI federDolore-SICD AIOM | Associazione Italiana di Oncologia Medica Federazione Cure Palliative Società Italiana Cure Palliative

3

🔄 October Highlights at FAAM! As we step into November, let’s take a moment to recap some of the incredible strides made last month 🌱 In October, we celebrated the ongoing growth of our group with Menarini S.p.A., which plays a key role in enhancing our strategic synergies. The batteries produced in Teverola, featuring in-house developed LFP cells, are now central to our shift toward a cell-to-vehicle model—directly integrating energy production into vehicles. This collaboration strengthens our position with a focus on cost efficiency, technological control, and innovation 🔋🌍 The #FAAMWave series kept rolling with our 11th episode, featuring Luca Cirillo, a talented Technical Designer whose passion for problem-solving and 3D design is pushing innovation forward. 🎮 His work on lithium cell integration is essential to our ongoing advancements. We also joined the IPCEI General Assembly in Lyon, where our R&D team reaffirmed FAAM’s commitment to building Europe’s sustainable battery future. It was a moment to share progress, insights, and visions for a resilient European production chain. 🌐 Lastly, our role in the strategic agreement between Eni and SERI Industrial Spa signifies our dedication to pioneering a lithium-iron-phosphate battery chain from production to recycling. This partnership underscores our commitment to making a real impact in Southern Italy and beyond. 🤝 Here's to more progress and sustainable growth ahead! 👏 #FAAM #SustainableEnergy #Innovation #BatterySolutions #EnergyTransition #MonthlyRecap

48